Compare Sterling Biotech with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs UNICHEM LAB - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH UNICHEM LAB STERLING BIOTECH/
UNICHEM LAB
 
P/E (TTM) x -0.4 61.1 - View Chart
P/BV x 0.0 0.7 2.2% View Chart
Dividend Yield % 0.0 2.1 -  

Financials

 STERLING BIOTECH   UNICHEM LAB
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
UNICHEM LAB
Mar-19
STERLING BIOTECH/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs11292 3.6%   
Low Rs3182 1.9%   
Sales per share (Unadj.) Rs26.8167.7 16.0%  
Earnings per share (Unadj.) Rs-15.0-3.6 412.0%  
Cash flow per share (Unadj.) Rs-5.55.9 -91.9%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %01.7 0.0%  
Book value per share (Unadj.) Rs54.9372.3 14.7%  
Shares outstanding (eoy) m267.8770.38 380.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.31.4 18.3%   
Avg P/E ratio x-0.5-65.3 0.7%  
P/CF ratio (eoy) x-1.339.9 -3.2%  
Price / Book Value ratio x0.10.6 19.9%  
Dividend payout %0-110.2 0.0%   
Avg Mkt Cap Rs m1,86216,680 11.2%   
No. of employees `0001.42.6 52.0%   
Total wages/salary Rs m5472,393 22.8%   
Avg. sales/employee Rs Th5,303.34,535.2 116.9%   
Avg. wages/employee Rs Th403.8919.8 43.9%   
Avg. net profit/employee Rs Th-2,959.0-98.2 3,013.1%   
INCOME DATA
Net Sales Rs m7,18111,801 60.9%  
Other income Rs m43984 4.3%   
Total revenues Rs m7,22312,785 56.5%   
Gross profit Rs m947-835 -113.4%  
Depreciation Rs m2,543674 377.5%   
Interest Rs m4,37775 5,820.6%   
Profit before tax Rs m-5,931-600 989.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,924-343 560.3%   
Profit after tax Rs m-4,007-256 1,567.9%  
Gross profit margin %13.2-7.1 -186.4%  
Effective tax rate %32.457.3 56.7%   
Net profit margin %-55.8-2.2 2,576.7%  
BALANCE SHEET DATA
Current assets Rs m14,33520,384 70.3%   
Current liabilities Rs m49,8095,029 990.4%   
Net working cap to sales %-494.0130.1 -379.7%  
Current ratio x0.34.1 7.1%  
Inventory Days Days403105 385.1%  
Debtors Days Days171135 126.5%  
Net fixed assets Rs m55,4329,023 614.3%   
Share capital Rs m268141 190.3%   
"Free" reserves Rs m13,93526,058 53.5%   
Net worth Rs m14,70126,199 56.1%   
Long term debt Rs m9,4780-   
Total assets Rs m73,98831,496 234.9%  
Interest coverage x-0.4-7.0 5.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.10.4 25.9%   
Return on assets %0.5-0.6 -87.5%  
Return on equity %-27.3-1.0 2,794.2%  
Return on capital %-6.4-2.0 321.4%  
Exports to sales %25.969.4 37.3%   
Imports to sales %0.20-   
Exports (fob) Rs m1,8608,188 22.7%   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,8608,188 22.7%   
Fx outflow Rs m25596 4.2%   
Net fx Rs m1,8357,592 24.2%   
CASH FLOW
From Operations Rs m1,719-3,278 -52.4%  
From Investments Rs m-3,148-2,860 110.1%  
From Financial Activity Rs m1,426-24 -5,892.6%  
Net Cashflow Rs m-3-4,690 0.1%  

Share Holding

Indian Promoters % 33.9 50.1 67.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 15.1 -  
FIIs % 9.9 3.0 330.0%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 31.7 124.0%  
Shareholders   21,482 20,176 106.5%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS